BioLargo’s PFAS Removal Technology Lands Drinking Water Treatment Project in New Jersey

Westminster, CA – December 20, 2023 – BioLargo, Inc. (OTCQB:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced that it received a purchase order for its Aqueous Electrostatic Concentrator (AEC) to be installed at a water treatment facility in Stockholm, New Jersey. BioLargo’s AEC is an eco-friendly water treatment technology for effectively removing per- and polyfluoroalkyl substances (PFAS) from contaminated water, including drinking water.

Compared to technologies like carbon filtration or ion exchange, the BioLargo AEC produces far less PFAS-laden waste during the PFAS removal process, significantly reducing potential hazardous waste disposal costs associated with PFAS remediation projects, and is able to remove all specified PFAS chemicals from water below EPA and state requirements.

Once the AEC system is installed, BioLargo will enter into an ongoing service contract for the maintenance of the system as well as the removal and disposal and destruction of the PFAS-laden waste.

John W. Clark, Jr. President of Lake Stockholm Systems, Inc. said, “After an extensive review of the available technologies, including input from our engineers and the state of New Jersey, we selected the BioLargo AEC to ensure the drinking water in our community was free of harmful PFAS chemicals. BioLargo’s solution will give us the peace of mind and guarantee that we can meet remediation requirements, both today and in the future.” 

BioLargo’s President and CEO Dennis P. Calvert commented, “Lake Stockholm Systems recognized our technology as a more eco-friendly, regulation-friendly, and cost-effective long-term solution for treating water contaminated by PFAS. We believe the success of this project will play a big role in attracting further municipal water treatment customers, many of whom are still under the misconception that carbon filtration or ion exchange are the only options for long-term PFAS remediation.”

Mr. Calvert continued, “Our technology reduces costs customers pay to dispose of the harmful and hazardous waste produced by any technology removing PFAS from water. For example, where a carbon system might produce 80,000 pounds of hazardous spent carbon at the end of its life, we can treat the same volume of water and produce less than five pounds of solid waste. With CERCLA and RCRA regulations looming, which will require handling PFAS-laden solid waste as hazardous materials, legacy technologies simply won’t be able to compete with the AEC in this area.”

Learn more at www.bestPFAStreatment.com.  

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com. 

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

BioLargo Benzinga All Access Interview - Dec 8, 2023

BioLargo Update at Emerging Growth Conference - December 7, 2023

 

BioLargo Battery Manufacturing Facility Update

 

BioLargo's Sodium-Sulfur Long Duration Energy Storage (LDES) small-scale battery manufacturing facility in Oak Ridge Tennessee. Status update for November, 2023.

About BioLargo's battery technology:

• Long-duration energy storage (LDES) battery technology that is safer (no runaway fire risk), longer-lasting, more energy-dense, and more efficient
• Proudly made in the USA with domestically and sustainably sourced components and materials. No rare earth metals
• Sealed, non-venting, no-maintenance design
• Eight years of R&D already completed, with a commercial-ready design
• Reduced total cost of operation for grid-scale storage compared to lithium-ion options
• Ideal for long-duration storage, offloading renewable energy, EV charging stations, commercial or residential charging stations

Battery laser welder

Hermetic fume hood

Atmosphere-Controlled Assembly Chamber

Control Panel for Belt Furnace

Belt Furnace

BioLargo at the Norwegian Embassy Sustainability Summit in Washington DC

 

In November 2023, BioLargo President and CEO Dennis P. Calvert was invited to speak at the Sustainability Summit at the Norwegian Embassy in Washington DC about the company's technologies that enable sustainable growth, like its advanced water treatment technologies and its safe, domestically sourced, long-lasting battery technology. 

All BioLargo's technologies are developed from the ground-up to make life better by solving tough environmental problems with sustainable technological strategies. Some of these problems include water contamination by per- and polyfluoroalkyl substances (PFAS) "forever chemicals", or the need for safe, long-lasting battery storage technologies made from sustainable materials. 

At the Sustainability Summit, BioLargo joined renowned business leaders and policymakers focused on sustainability, sustainable packaging, environmental stewardship, and more, with a focus on collaboration between the United States and Norway.

Dennis with Congresswoman Young Kim 

BioLargo Q3 2023 Earnings Results Webcast and Conference Call on Monday, November 20, 2023 – 6:00 PM Eastern Time

Westminster, CA – November 20, 2023 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and full-service environmental engineering company, announced it will host an investor webcast and conference call on Monday, November 20, 2023, at 3:00 pm Pacific / 6:00 pm Eastern. The event, which will be open to the public, will be held to review the company’s financial results for the quarter ended September 30, 2023, discuss recent milestones, and conduct a question-and-answer session.

To listen to a live broadcast, go to the site linked below at least 15 minutes prior to the scheduled start time to register and download any necessary audio/video software.

To participate in the live webcast and teleconference:

Webcast Link:	https://www.webcaster4.com/Webcast/Page/2448/49451
Teleconference Domestic:	888-506-0062
Teleconference International: Participant Access Code:	973-528-0011 360101

 

To watch or listen to a replay of the webcast or teleconference:

 

Webcast Replay Expiration:	Saturday, February 17, 2024
Teleconference Replay Expiration:	Monday, December 04, 2023
Teleconference Replay Domestic:	877-481-4010
Teleconference Replay:	919-882-2331
Replay Passcode:	49451

The webcast replay and accompanying presentation materials will be made available for a limited time on the Investor Relations section of BioLargo’s website at www.biolargo.com/investor-relations.

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com.   Learn more about the company’s PFAS treatment solutions at www.bestpfastreatment.com.  

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”)  anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

BioLargo Breaks Another Revenue Record

 

$7.9 Million in revenue is 108% over first nine months of 2022

Westminster, CA – November 15, 2023 – BioLargo, Inc. (OTCQB:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, reported $7.9 million in revenues over the nine months ended September 30, 2023, a 108% increase over the same period in 2022 in its Form 10-Q filed with the SEC, putting it on a pace to exceed $10 million in annual revenues for the first time (see www.biolargo.com/sec-filings).

BioLargo will hold an investor webcast on Monday, November 20, 2023, at 3:00 pm Pacific / 6:00 pm Eastern, at the following link, open to the public, to discuss the quarterly report: https://www.webcaster4.com/Webcast/Page/2448/49451

Dennis P. Calvert, the company’s President and CEO, said, “Company-wide revenues are rising again. Through Q3, we have already surpassed last year’s annual revenues by 34%, with another quarter to go. Pooph pet-odor product sales are climbing steadily as our partners continue to expand retail presence around the country.”

He continued, “Over the summer, our PFAS team has been approached by a broad base of prospective customers in diverse industries, including municipalities, government agencies, drinking water systems, firefighting foam projects, wastewater entities, and industrial facilities. The excitement about our PFAS collection and destruction solution has been highly validating to our value proposition to the marketplace. Our engineers have commenced work on a project to remove PFAS from a municipal drinking water supply in New Jersey, and we look forward to sharing more details as they come available.”

On the topic of the company’s new safe, long-lasting battery technology, Mr. Calvert said, “Finally, I'm happy to report that substantial progress has been made in the construction of our Oak Ridge, Tennessee manufacturing facility for the prototypes of our safe, longer-lasting long duration energy storage (LDES) battery technology. We hope to have batteries built and being tested by year’s end.”

The following are some highlights from BioLargo’s quarterly report filed November 14, 2023, and are not a substitute for the details in the 10-Q, which can be found here: https://www.biolargo.com/sec-filings. All interested parties are encouraged to review the full quarterly report filed with the SEC to get the most complete information about BioLargo and its growing cleantech business.

• Consolidated revenues for the three months ended September 30, 2023, were $2,672,000, a 78% increase over the same period in 2022, and an 85% increase over the three months ended June 30, 2023.
• As of September 30, 2023, year-to-date revenues were $7,860,000, a 108% increase over the same period of 2022, and 34% increase over the entirety of 2022, with one quarter still remaining in 2023.
• Net loss for the three months ended September 30, 2023, was $1,508,000, compared to $847,000 in the same period of 2022, and $1,626,000 for the three months ended June 30, 2023, with a notable increase in R&D to $694,000 associated with Clyra and the building of the company’s prototype manufacturing line for its sodium sulfur battery technology.
• ONM Environmental, Inc., BioLargo’s odor and VOC control subsidiary, generated $2,513,000 of revenue, of which $529,000 resulted from a record-breaking quarter of sales of the company’s odor and VOC control product CupriDyne® Clean and related services to industrial and solid waste customers.

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com.  Learn more about the company’s PFAS treatment solutions at www.bestpfastreatment.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Sequire Spotlight Presents BioLargo, Inc. (BLGO): Environmental Solutions for a Sustainable Future

Source: Microcaps.com

Host Marc Lopresti interviews President & CEO, Dennis Calvert. He talks about their innovative solutions to solve big problems, turning negatives into positives.

BioLargo at Emerging Growth Conference - Video

 BioLargo CEO Dennis Calvert presented at the virtual Emerging Growth Conference this week. Didn't catch it live? Watch below - he covers our PFAS technology commercialization advancements, Pooph growth, and much more!

BioLargo at Sustain SoCal's Water Solutions 8

BioLargo was honored to be a platinum sponsor of last week's Sustain SoCal Water Solutions 8 conference, focused on innovation and innovators in the water space in Southern California. There were fascinating talks by key local groups including the Moulton Niguel Water District and Metropolitan Water District of Southern California.

Our own presentation at the event focused on BioLargo's solutions for removing and destroying per- and polyfluoroalkyl substances (PFAS) that contaminates groundwater and drinking water around the state and across the country. Our Aqueous Electrostatic Concentrator (AEC) system can meet or beat the EPA's proposed new drinking water standards, while creating a tiny fraction of the amount of PFAS-contaminated solid waste compared to carbon-based capture systems. Then, we handle the customer's waste, cradle-to-grave.

So many interesting presentations at this year's events, including by SkyH2O's Alexander von Welczeck, whose company's "SkyH2O stations" can provide clean, safe drinking water anywhere by pulling it out of the atmosphere.

Also of note - a very interesting talk about battery energy storage systems (BESS) being deployed at wastewater treatment operations to ensure constant operation even in the face of fluctuating or interrupted electrical supply from the grid. 

A special thanks to Sustain SoCal's Scott Kitcher, who not only put on another highly successful innovation-centric water event, but also heads such an amazing industry group that catalyzes partnership and collaboration to further our shared goal of making OC a hub for water innovation.

BioLargo’s YTD Revenues Up 127% Compared to Last Year Period

Following extraordinary Q1, quarter-over-quarter sales were down as company supported inventory build-up for national retailers; six month revenue ($5.2 million) was 88% of last year’s total revenue ($5.9 million)

Westminster, CA – August 15, 2023 – BioLargo, Inc. (OTCQB:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, yesterday filed its Quarterly Report (www.biolargo.com/sec-filings). Company management below provides a summary of the report’s highlights.

BioLargo will hold an investor webcast on Wednesday, August 16, 2023, at 3:00 pm Pacific / 6:00 pm Eastern, at the following link, open to the public: https://www.webcaster4.com/Webcast/Page/2448/48925

Dennis P. Calvert, BioLargo’s President and CEO, said, “2023 is shaping up to be a great year. We are especially excited as the Pooph team continues its national advertising campaign and successfully adds more retailers to carry the product. They aim to secure contracts for more than 20,000 retail stores to carry the product and those efforts are underway.  We have witnessed first-hand how the team at Pooph executes with precision and will continue to support these ambitious goals.”

Financial highlights from the quarterly report are as follows – all interested parties are encouraged to review the full quarterly report filed with the SEC to get the most complete information about BioLargo and its growing cleantech business.

• Consolidated revenues for the three months ended June 30, 2023, were $1,446,000, a 9% increase over the same period in 2022, and a 61% decrease over the three months ended March 31, 2023.
• The company’s revenues through June 30, 2023 were $5,188,000, a 127% increase over the same period of 2022.
• Net loss for the three months ended June 30, 2023, was $1,626,000, compared to $1,333,000 in the same period in 2022, and $425,000 for the three months ended March 31, 2023.
• Net stockholders’ equity at June 30, 2023, rose to $4,120,000 from $3,550,000 at March 31, 2023.

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com. 

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

BioLargo Q2 2023 Earnings Results Webcast and Conference Call on Wednesday, August 16, 2023 - 6:00 PM Eastern Time

Westminster, CA – August 11, 2023 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and full-service environmental engineering company, announced it will host an investor webcast and conference call on Wednesday, August 16th, 2023, at 3:00 pm Pacific / 6:00 pm Eastern. The event, which will be open to the public, will be held to review the company’s financial results for the three months ended June 30th, 2023, discuss recent milestones, and conduct a question-and-answer session.

To listen to a live broadcast, go to the site linked below at least 15 minutes prior to the scheduled start time to register and download any necessary audio/video software.

To participate in the live webcast and teleconference:

Webcast Link: https://www.webcaster4.com/Webcast/Page/2448/48925

Teleconference Domestic: 888-506-0062

Teleconference International: 973-528-0011

Participant Access Code: 590380

To watch or listen to a replay of the webcast or teleconference:

Webcast Replay Expiration: Friday, November 17, 2023

Teleconference Replay Expiration: Thursday, August 30, 2023

Teleconference Replay Domestic: 877-481-4010

Teleconference Replay International: 919-882-2331

Replay Passcode:  48925

The webcast replay and accompanying presentation materials will be made available on the Investor Relations section of BioLargo’s website at www.biolargo.com/investor-relations. 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative technologies in the cleantech space, including for PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our approach is to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. We have developed a number of key channel partnerships to support the reach of our products and services and maximize their commercial potential. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 90 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.   

Contact Information

Dennis P. Calvert 

President and CEO, BioLargo, Inc. 

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Sequire Spotlight Presents BioLargo (BLGO): Sustainable Solutions to Make Life Better

 Source: Sequire Spotlight

Host Jonathan Miller interviews CEO: Dennis P. Calvert. He provides information about their technologies removing harmful airborne contaminants, including volatile organic compounds, odors, and pathogens.

BioLargo – Innovative CleanTech Company Combating "Forever Chemicals" Talks Impressive Q1 Numbers

 Source: Johnny Rice, Benzinga Staff Writer (https://www.benzinga.com/tech/23/06/33021698/biolargo-innovative-cleantech-company-combating-forever-chemicals-talks-impressive-q1-numbers) 

Dennis Calvert, President & CEO of BioLargo, Inc (OTCQB:BLGO) was recently a guest on Benzinga’s All-Access.

BioLargo is a cleantech and life sciences innovator and engineering services solution provider. Its core products address Per- and Polyfluorinated Substances (PFAS) contamination, achieve advanced water and wastewater treatment, control odor and Volatile Organic Compounds (VOCs), improve air quality and control infections and infectious disease.

The company just announced its financials for the first quarter of 2023. Mr. Calvert spoke regarding the positive numbers which included a near 300% growth in revenue for the quarter year-over-year.

Watch the full interview here:

BioLargo, Inc. Discusses Record-Breaking Financial Results, Innovation-Pipeline Business Model, and More with The Stock Day Podcast

Phoenix, Arizona--(Newsfile Corp. - June 5, 2023) - The Stock Day Podcast welcomed BioLargo, Inc. (OTCQB: BLGO), a cleantech and life sciences innovator and engineering services solution provider. President and CEO of BioLargo, Inc., Dennis P. Calvert, joined Stock Day host Kevin Davis.

The interview covered the following topics:

• The company's first quarter financial results, including increased revenues from sales of private-label pet odor product Pooph (www.pooph.com),
• Progress at the company's engineering group,
• Progress at subsidiary Clyra Medical and its Bioclynse surgical wound irrigation solution,
• The company's overall innovation development cycle; and
• The company's sodium-sulfur battery technology.

"What we're going to witness, we believe, is exactly what's happening at Pooph has the potential to happen for all the other operating assets in the portfolio," said Mr. Calvert. "In each case, we've done the hardest work to invent, prove up, find first commercial adoption, and then find distribution through partnerships."

To hear Dennis Calvert's entire interview, follow the link to the podcast here: https://audioboom.com/posts/8312041-biolargo-inc-discusses-record-breaking-financial-results-innovation-pipeline-business-model-a.

Investors Hangout is a proud sponsor of "Stock Day," and Stock Day Media encourages listeners to visit the company's message board at https://investorshangout.com/.

About The "Stock Day" Podcast

Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America.

SOURCE:
Stock Day Media
(602) 821-1102

About BioLargo, Inc.

BioLargo, Inc. (OTCQB: BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Its core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, and control infections and infectious disease. Its business approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. www.BioLargo.com

Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding anticipated revenue and plans for future operations, and may be identified by words such as "we believe". These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company's business, results of operations, financial condition, and stock price; the effect of global and regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

BioLargo Announces 288% Revenue Growth in Quarterly Report

Company’s revenues grew 288% compared to the same period last year, and grew 78% compared to the fourth quarter of 2022. The company’s net loss dropped by 68% from the same period last year.

Westminster, CA – May 17, 2023 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, yesterday filed its Quarterly Report for the three months ended March 31, 2023 (www.biolargo.com/sec-filings). Company management below provides a summary of the quarterly report’s highlights.

BioLargo will hold an investor webcast on Thursday, May 18, 2023, at 1:30 pm Pacific / 4:30 pm Eastern, at the following link, open to the public: https://www.webcaster4.com/Webcast/Page/2448/48436

Dennis P. Calvert, the company’s President and CEO, said, “We’re confident that the long-term success of our pet odor control product partnership – Pooph – bolstered by the rollout of key water treatment technologies, will drive our company to our goal of profitability and beyond.”

Company management provides highlights of the quarterly report below, but encourages investors to review the full report to get the most complete information about BioLargo and its growing cleantech business.

Highlights:

• Consolidated revenue for the three months ended March 31, 2023, was $3,742,000, which was a 288% increase over the same period in 2022, and a 78% increase over the previous quarter (Q4 of 2022).
• The company’s net loss was reduced by 68% compared to the same period in 2022, to $494,000.
• Net stockholders’ equity rose to $3,552,000 from $2,011,000 in the fourth quarter of 2022.
• The company ended the quarter with $3,264,000 in cash, compared to $1,851,000 at December 31, 2022.
• A standout performer in BioLargo’s portfolio was ONM Environmental, the company’s odor and VOC control subsidiary, whose revenues grew 491% compared to the same period of 2022, to $3,543,000. ONM Environmental’s operating income also grew 10,569% from the same period of 2022, to $1,387,000. The subsidiary’s significant growth in revenue is largely attributed to the growing success of the pet odor control product Pooph, sold by the company’s partners at Ikigai Marketing Works, LLC, which comprised 90% of its revenues (and 86% of BioLargo company-wide revenues).
• Revenues at BioLargo Engineering, Science & Technologies, LLC decreased by 45% to $193,000, as compared to the same period in 2022, and its operating loss increased to $368,000, as compared to $35,000 in the same period in 2022.

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com. 

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding tanticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

BioLargo Q1 2023 Earnings Results Webcast and Conference Call on Thursday, May 18, 2023 - 4:30 PM Eastern Time

Westminster, CA – May 17, 2023 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and full-service environmental engineering company, announced it will host an investor webcast and conference call on Thursday, May 18, 2023, at 1:30 pm Pacific / 4:30 pm Eastern. The event, which will be open to the public, will be held to review the company’s financial results for the three months ended March 31, 2023, discuss recent milestones, and conduct a question-and-answer session.

To listen to a live broadcast, go to the site linked below at least 15 minutes prior to the scheduled start time to register and download any necessary audio/video software.

To participate in the live webcast and teleconference:

Webcast Link:	https://www.webcaster4.com/Webcast/Page/2448/48436
Teleconference Domestic:	888-506-0062
Teleconference International: Participant Access Code:	973-528-0011 918886

 

To watch or listen to a replay of the teleconference:

 

Teleconference Replay Expiration:	Wednesday, May 31, 2023
Teleconference Replay Domestic:	877-481-4010
Teleconference Replay International:	919-882-2331
Replay Passcode:	48436

 

The webcast replay and accompanying presentation materials will be made available for 90 days on the Investor Relations section of BioLargo’s website at www.biolargo.com/investor-relations.

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com.    

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

 

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Dennis Calvert Interview with Kenny Polcari

BioLargo's President and CEO Dennis P. Calvert sat down for an interview with Kenny Polcari, renowned finance and investor intelligence expert and financial commentator for Fox News, CNBC, and CNN, and more. In this interview, Dennis does a deep dive on what's driving BioLargo's growth, including expanded rollout of Pooph pet odor control products in Walmart stores across the country, the commercial launch of the company's PFAS technology, and its newly acquired sodium-sulfur battery energy storage technology.

Watch the full interview here:

About Kenny Polcari

Polcari is currently the Managing Partner of Kace Capital Advisors, Chief Market Strategist at SlateStone Wealth, sits on the Advisory Board of The Headstrong Project, and is a member of the National Organization of Investment Professionals. He is a Fox Business, CNBC, and CNN financial commentator. He started his career on the floor of the New York Stock Exchange as an institutional broker starting in 1985 and graduated from Boston University, School of Management in 1983 with a Bachelor of Science in Business Administration with a concentration in Finance.

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com.  

Contact Information

Dennis P. Calvert 

President and CEO, BioLargo, Inc. 

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Proactive Investors Interview: BioLargo increasing revenue highlighted by achieving operations net positive cash for first time

 Source: Proactive Investors (https://www.proactiveinvestors.com/companies/news/1011579/biolargo-increasing-revenue-highlighted-by-achieving-operations-net-positive-cash-for-first-time-1011579.html)

BioLargo CEO Dennis Calvert joins Natalie Stoberman from the Proactive studios to share its latest earnings call highlighted by a 132% increase in revenues over 2021, and a 26% decrease in net loss.

Calvert says this growth is highlighted by the company achieving net positive cash from operating activities. Calvert adds that 2022 was BioLargo's strongest year in terms of financial performance, with its Pooph pet odor remover product revenues escalating as it rolls into Walmart stores in the U.S.

BioLargo Annual Report Highlights 132% Annual Revenue Increase, Reduced Net Loss

Westminster, CA – April 3, 2023 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, announced that its Annual Report, filed March 31, 2023, showed a 132% increase in revenues over 2021, and a 26% decrease in net loss (www.biolargo.com/sec-filings). Company management below provides a summary of the annual report’s highlights, including the company’s financial performance and progress of key projects.

BioLargo will hold an investor webcast today, Monday, April 3, 2023, at 1:30 pm Pacific / 4:30 pm Eastern, at the following link, open to the public: https://www.webcaster4.com/Webcast/Page/2448/47877

Dennis P. Calvert, the company’s President and CEO, said, “2022 was our strongest year yet in terms of financial performance, and we are eager for the day when our valuation reflects the significance of our ongoing success. With Pooph revenues leading the way and other key catalysts like our PFAS treatment business just now coming online, we’re confident that this year will herald even more significant growth at the company.”

Company management provides highlights of the annual report below, but encourages investors to review the full report to get the most complete information about BioLargo and its growing cleantech business, including the risk factors beginning at page 12.

Key financial highlights:

• Consolidated revenue for the year ended December 31, 2022, was $5,884,000, which was a 132% increase over 2021. Revenue in the fourth quarter of 2022 was $2,096,000, a 40% increase as compared with the third quarter of 2022 (quarter-over-quarter), and a 167% increase as compared with the fourth quarter of 2021.
• The company no longer has any outstanding convertible debt.
• The company’s total net loss for the year ended December 31, 2022, was reduced by 26% as compared with the prior year, from $6,894,000 to $5,132,000. Approximately 50% of the company’s net loss was due to non-cash expenses, including $2,071,000 of stock option compensation expense, and $291,000 of services paid by the issuance of our common stock. Net cash used in operations decreased 30% to negative $2,760,000.
• Net stockholders’ equity rose from $933,000 at the end of 2021 to $2,011,000 at the end of 2022.
• The company ended the year with $3.1 million in current assets and working capital of $1.6 million.

Key commercial and developmental highlights:

• Revenues from sales of the Pooph pet odor control product to Ikigai Marketing Works have escalated significantly, resulting from the ongoing success of Ikigai’s national marketing campaign for the product and its rollout into Walmart stores in the US.
• The company’s AEC water treatment system has been tested and proven to remove per- and polyfluoroalkyl substances (PFAS) from water to below levels required by the EPA’s recently proposed limitations of four parts per trillion. These so-called “forever chemicals” accumulate in the human body, are linked to multiple health issues, and are more and more the subject of government regulatory concern.  
• The company acquired the IP rights to a sodium-sulfur battery, a technology with unique technical features that enable it to address a need in the market for safe, affordable, long-term energy storage at grid-scale, at electric vehicle charging stations, or similar static applications. The technology is already developed, and BioLargo has formed and secured seed capital for a new subsidiary which will lead the manufacturing, scale-up, and operations for the new technology.

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com. 

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.